Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases

Autor: Attauabi, M, Hoglund, C, Fassov, J, Pedersen, K B, Hansen, H Bansholm, Wildt, S, Jensen, M Dam, Neumann, A, Lind, C, Jacobsen, H Albaek, Popa, A M, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, J B, Johan, B

Publikováno v: Attauabi, M, Höglund, C, Fassov, J, Bo Pedersen, K, Hansen, H B, Wildt, S, Dam Jensen, M, Neumann, A, Lind, C, Jacobsen, H A, Popa, A M, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, J B & Johan, B 2021, ' Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy-A real-world nationwide cohort of patients with inflammatory bowel diseases ', Journal of Crohn's and Colitis, vol. 15, no. Suppl. 1, P347, pp. S369–S370 . https://doi.org/10.1093/ecco-jcc/jjab076.471
Attauabi, M, Hoglund, C, Fassov, J, Pedersen, K B, Hansen, H B, Wildt, S, Jensen, M D, Neumann, A, Lind, C, Jacobsen, H A, Popa, A M, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, J B & Johan, B 2021, ' Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy-A real-world nationwide cohort of patients with inflammatory bowel diseases ', Journal of Crohn's & colitis, vol. 15, no. Suppl. 1, pp. S369-S370 . https://doi.org/10.1093/ecco-jcc/jjab076.471

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c11e9ac186de1aa9d1bd72008019a413
https://portal.findresearcher.sdu.dk/da/publications/9f2725ba-6ae4-43ec-aa60-2f50f5f38ab1